KDM6B and rheumatoid arthritis: Silencing JMJD3 or applying GSK-J4 to inhibit the activity of JMJD3 can drastically downregulate inflammatory factors induced by IL-1β by affecting the level of H3K27me3 in the promoter in joint fibroblasts of patients with rheumatoid arthritis [28].